TABLE 1.

Descriptive characteristics of the included cohort studies

First author, PY	Study design	Country	Cutoff age (years)	No. of patients	T stage	N stage	Outcomes
Jones, 1989 54	NA	Canada	40	71	NA	NA	OS
Siegelman, 1998 48	R	USA	45	87	Any	Any	OS, DFS
Friedlander, 1998 42	R	USA	40	72	Any	Any	DFS
Yoshida, 1999 55	NA	Japan	40	568	T1, T2	N0	OS, DSS
Al Rajhi, 2000 56	NA	Saudi Arabia	45	85	T1, T2	N0	OS, DSS
Vargas, 2000a 46	R	USA	40	34	Any	Any	OS, DFS
Pitman, 2000 43	R	USA	40	272	Any	Any	DFS
Davidson, 2001 57	P	USA	40	819	NA	NA	OS, DSS
Veness, 2003 47	R	Australia	40	164	Any	Any	OS, DFS
Hyam, 2003 36	R	Australia	40	144	Any	Any	OS
Popovtzer, 2004 39	P/R	Israel	45	48	T1, T2	Any	OS, DSS
Liao, 2006 45	P	Korea	40	296	Any	Any	OS, DSS, DFS
Garavello, 2007 17	P	Italy	40	138	Any	Any	OS, DSS, DFS
Lee, 2007 58	R	Taiwan	45	40	Any	Any	OS, DSS
Lim, 2007 59	R	Korea	45	32	T2	N0	OS, DSS
Yang, 2008 60	P	China	40	229	Any	Any	OS
Park, 2010 38	R	Korea	40	85	Any	Any	OS, DSS
Soudry, 2010 44	R	Israel	30	85	Any	Any	OS, DSS, DFS
Kies, 2012 61	R	USA	40	23	T2, T3	N0–N2	OS, DSS
Kabeya, 2012 62	R	Japan	40	32	Any	Any	OS, DFS
Hilly, 2013 18	R	Israel	30	78	Any	Any	OS, DSS, DFS
Chen, 2016 63	P	Taiwan	40	128	Any	Any	DSS
Sgaramella, 2015 64	NA	Italy, Sweden	40	129	Any	Any	OS
Santana, 2017 21	R	Brazil	45	82	Any	Any	DSS, DFS
Mroueh, 2017 41	R	Finland	40	563	Any	Any	OS, DSS
Cassidy, 2017 65	R	USA	45	180	Any	N0	OS
Blanchard, 2017 40	R	France	40	100	Any	Any	OS, DSS
Knopf, 2015 66	R	Germany	45	276	Any	Any	OS, DSS
Chen, 2018 67	R	China	45	101	Any	Any	OS
Farquhar, 2018 68	R	USA	45	397	Any	Any	OS, DSS
Oliver, 2019 4	R	USA	40	22,930	Any	Any	OS

PY, Publication year; P, prospective; R, retrospective; NA, not available; DFS, disease‐free survival; DSS, disease‐specific survival; OS, overall survival. DFS may also include local recurrence‐free survival, regional recurrence‐free survival, and distant recurrences‐free survival.

^aStudy included only women.